Seasonal malaria chemoprevention in northern Mozambique: a cost-effectiveness analysis [PDF]
Background Malaria is endemic in Mozambique and one of the leading causes of death in children under 5 years old. In 2020 the country adopted the WHO-recommended seasonal malaria chemoprevention (SMC) strategy and delivered the intervention in all 23 ...
Neide Canana +9 more
doaj +6 more sources
Prevalence of malaria in an area receiving seasonal malaria chemoprevention in Niger [PDF]
Background Malaria transmission is highly seasonal in Niger. Despite the introduction of seasonal malaria chemoprevention (SMC) in the Magaria District, malaria incidence remains high, and the epidemiology of malaria in the community is not well ...
Matthew E. Coldiron +11 more
doaj +4 more sources
Trends in uncomplicated and severe malaria following seasonal malaria chemoprevention administration in Nouna, Burkina Faso: a quasi-experimental pre-post study [PDF]
Background While Seasonal Malaria Chemoprevention (SMC) has been adopted as a malaria control strategy in regions with seasonal transmission, continued monitoring and evaluation of its effectiveness across diverse ecological, epidemiological, and ...
Elisabeth A. Gebreegziabher +12 more
doaj +5 more sources
Status and prospects of seasonal malaria chemoprevention among children in Sahelian countries: A systematic review and meta-analysis. [PDF]
In areas with seasonal malaria transmission, seasonal malaria chemoprevention (SMC) involves giving children a three-day course of sulfadoxine-pyrimethamine and amodiaquine once a month during the transmission season.
Medard Djedanem +4 more
doaj +3 more sources
Assessing the Acceptability and Feasibility of Five Cycles of Seasonal Malaria Chemoprevention in Côte d’Ivoire [PDF]
Seasonal malaria chemoprevention (SMC) is a strategy recommended by the World Health Organization for children aged 3–59 months in the Sahel and sub-Sahel regions where malaria transmission is seasonal.
Orphée Kangah +3 more
doaj +4 more sources
Household-level effects of seasonal malaria chemoprevention in the Gambia. [PDF]
Abstract Background In 2022 the WHO recommended the discretionary expansion of the eligible age range for seasonal malaria chemoprevention (SMC) to children older than 4 years. Older children are at lower risk of clinical disease and severe malaria so there has been uncertainty about the cost ...
Soremekun S +11 more
europepmc +9 more sources
Abstract Vaccines, monoclonal antibodies, and long-acting injectables are being developed to prevent Plasmodium falciparum malaria. These therapeutics may target multiple stages of the parasite life cycle; evidence is needed to articulate their benefits with chemoprevention and prioritise candidates for clinical development.
Braunack-Mayer L +5 more
europepmc +3 more sources
Dihydroartemisinin-piperaquine effectiveness for seasonal malaria chemoprevention in settings with extended seasonal malaria transmission in Tanzania [PDF]
Effectiveness of dihydroartemisinin-piperaquine (DP) as seasonal malaria chemoprevention (SMC) was assessed in Nanyumbu and Masasi Districts. Between March and June 2021, children aged 3–59 months were enrolled in a cluster randomized study.
Richard Mwaiswelo +7 more
doaj +4 more sources
Seasonal Malaria Chemoprevention: An Evolving Research Paradigm. [PDF]
Robert W. Snow discusses the importance of empirical evidence, such as that provided in the trial published this week by Milligan and colleagues, in guiding malaria control in Africa.
Robert W Snow
doaj +4 more sources
Seasonal malaria chemoprevention: successes and missed opportunities [PDF]
Seasonal malaria chemoprevention (SMC) was recommended in 2012 for young children in the Sahel during the peak malaria transmission season. Children are given a single dose of sulfadoxine/pyrimethamine combined with a 3-day course of amodiaquine, once a ...
Matthew E. Coldiron +2 more
doaj +3 more sources

